| Product Name | Tyrphostin 9 |
| Description |
Tyrosine Kinase Inhibitor |
| Purity | >99% (TLC); NMR (Conforms) |
| CAS No. | 10537-47-0 |
| Molecular Formula | C18H22N2O |
| Molecular Weight | 282.4 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | May be dissolved in DMSO (25 mg/ml); or ethanol (20 mg/ml) |
| Source | Synthetic |
| Appearance | Orange crystalline powder; MP=139-140°C |
| SMILES | CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C(C#N)C#N |
| InChI | InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3 |
| InChIKey | MZOPWQKISXCCTP-UHFFFAOYSA-N |
| Safety Phrases |
Classification: Danger. Hazard statement(s): H301 + H311 Precautionary statement(s): P280 - P301 + P310 + P330 - P302 + P352 + P312 |
| Cite This Product | Tyrphostin 9 (StressMarq Biosciences | Victoria, BC CANADA | Catalog# SIH-641) |
| Alternative Names | 3,5-Di-tert-butyl-4-hydroxybenzylidene-malononitrile; Tyrphostin A9; Malonoben; AG-17; SF 6847; RG-50872 |
| Research Areas | Apoptosis, Cancer, Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein |
| PubChem ID | 5614 |
| Scientific Background |
Tyrphostin A9 is a well‑characterized inhibitor of PDGF receptor tyrosine kinase, exhibiting an IC₅₀ of 1.2µM. It also functions as a potent inhibitor of oxidative phosphorylation at nanomolar concentrations (10nM). Beyond its primary kinase‑related effects, Tyrphostin A9 suppresses cellular proliferation by disrupting mitochondrial integrity and perturbing Golgi complex organization. These actions collectively contribute to its ability to block the growth of vascular smooth muscle cells. Of particular relevance to neuroscience, Tyrphostin A9 has been shown to induce mild mitochondrial uncoupling in midbrain dopaminergic (mDA) neurons. This mitochondrial modulation is associated with a reduction in intracellular α‑synuclein levels, suggesting a potential therapeutic angle for disorders characterized by α‑synuclein accumulation. |
| References |
1. GE Bilder et al. Am. J. Physiol. 1991; 260:C721. 2. H Terada et al. Biochim. Biophys. Acta 1981; 639:225. 3. AM Berger et al. Cancer Res. 1995; 55:2794. 4. J Thyberg. Eur. J. Cell Biol. 1998; 76:33. 5. V Gorgogietas et al. Sci. Rep. 2025; 15:29507: https://pubmed.ncbi.nlm.nih.gov/40796766/ |
Reviews
There are no reviews yet.